# Antônio Rossi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/antonio-rossi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 13,987 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 52 |
| i10-index | 246 |
| Last Known Institution | Università Campus Bio-Medico |
| OpenAlex ID | https://openalex.org/A5032078755 |
| ORCID iD | 0000-0003-3295-0345 |
| Works | 620 |

## Researcher papers

- [Non-small-cell lung cancer](https://scholariq.org/papers/non-small-cell-lung-cancer/)
- [Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach](https://scholariq.org/papers/definition-assessment-and-treatment-of-wheezing-disorders-in-preschool-children/)
- [Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial](https://scholariq.org/papers/chemotherapy-for-elderly-patients-with-advanced-non-small-cell-lung-cancer-the/)
- [Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data](https://scholariq.org/papers/carboplatin-or-cisplatin-based-chemotherapy-in-first-line-treatment-of-small/)
- [A chart of failure risk for noninvasive ventilation in patients with COPD exacerbation](https://scholariq.org/papers/a-chart-of-failure-risk-for-noninvasive-ventilation-in-patients-with-copd/)
- [Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles](https://scholariq.org/papers/platinum-based-chemotherapy-in-advanced-non-small-cell-lung-cancer-optimal/)
- [A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy](https://scholariq.org/papers/a-randomized-phase-iii-study-evaluating-the-efficacy-and-safety-of-nepa-a-fixed/)
- [First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial](https://scholariq.org/papers/first-line-erlotinib-followed-by-second-line-cisplatin-gemcitabine-chemotherapy/)
- [Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study](https://scholariq.org/papers/efficacy-and-safety-of-nepa-an-oral-combination-of-netupitant-and-palonosetron/)
- [Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study](https://scholariq.org/papers/clinical-outcomes-of-patients-with-advanced-cancer-and-pre-existing-autoimmune/)
- [Intrapatient Molecular and Histologic Heterogeneity After First-generation or Second-generation TKI Therapy of NSCLC Patients](https://scholariq.org/papers/intrapatient-molecular-and-histologic-heterogeneity-after-first-generation-or/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer therapeutics and mechanisms](https://scholariq.org/topics/cancer-therapeutics-and-mechanisms/)

## Researcher university

- [Università Campus Bio-Medico](https://scholariq.org/institutions/universita-campus-bio-medico/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.